Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

On location

First-in-Human Study Finds FF-10101-01 Has Clinical Activity in Relapsed/Refractory FLT3-Mutated AML

For patients with relapsed and/or refractory FLT3-mutated acute myeloid leukemia (AML), treatment with the selective and irreversible FLT3 inhibitor FF-10101-01 had promising clinical activity....
On location

Investigators Identify Distinct Molecular Subgroups to Guide Treatment Decisions in AML

Analyzing genetic data from more than 3,000 patients with acute myeloid leukemia (AML), researchers from Memorial Sloan Kettering Cancer Center identified 14 distinct molecular...

Post-Transplant MRD Monitoring With Non-DTA Mutations Predicts Outcomes in AML

In next-generation sequencing (NGS)-based measurable residual disease (MRD) monitoring, the use of non-DNMT3A, TET2, or ASXL1 (non-DTA) mutations may predict relapse and survival following...

Are Physician Perceptions of Transfusions a Barrier to Hospice Enrollment for Patients With AML?

Patients with acute myeloid leukemia (AML) and their caregivers generally defer end-of-life (EOL) transfusion decisions to clinicians without participating in shared decision-making. This tendency...
WIB_icon

Survival Outcomes After HLA-Haploidentical Relative Versus Matched Unrelated Donor Transplant in Acute Leukemias and...

In patients with acute leukemias or myelodysplastic syndromes (MDS), those who underwent haploidentical relative hematopoietic cell transplantation (haploHCT) had higher rates of grade 3-4...
WIB_icon

Less-Intensive Therapies Increase Mortality Risk, But Decrease Hospital Stay, in Older Patients With AML

Although the use of less-intensive therapies is associated with an increased risk of mortality in older patients with acute myeloid leukemia (AML), patients treated...

FDA Clears IND Application for Gamma Delta T-Cell Therapy

The FDA has cleared an investigational new drug (IND) application for GDX012 to be examined as a therapy for patients with hematologic malignancies. GDX012...
On location

Venetoclax Added to Intensive Chemotherapy Is Safe, Effective in Relapsed/Refractory AML

In a study presented at EHA2021 Virtual, the annual congress of the European Hematology Association, adding short-term venetoclax to an intensive FLA-IDA chemotherapy regimen...
On location

Olutasidenib Shows Promise for Relapsed/Refractory IDH1-Mutated Acute Myeloid Leukemia

Olutasidenib, an investigational IDH1 inhibitor selective for mutant IDH1, was well tolerated and associated with durable complete remissions (CRs) in patients with high-risk, relapsed/refractory...
On location

How Do Perceptions about Side Effects Influence Treatment Decisions and Outcomes in AML?

Patients’ negative perception of the side effects of intensive chemotherapy (IC) for acute myeloid leukemia (AML) may be associated with undertreatment and worse outcomes,...
Advertisement

Current Issue

July 2021 Bonus Mid-Year Edition, Volume 7 Issue 9

This issue features conversations with ASH Clinical Research Training Institute graduates, highlights from the virtual ASCO and EHA annual meetings, and more.

Block title